Skip to main content
SpringerLink
Log in

Plant specific N-glycans do not have proven adverse effects in humans

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Piron, R., Santens, F., De Paepe, A., Depicker, A. & Callewaert, N. Nat. Biotechnol. 33, 1135–1137 (2015).

    Article  CAS  PubMed  Google Scholar 

  2. Meuris, L. et al. Nat. Biotechnol. 32, 485–489 (2014).

    Article  CAS  PubMed  Google Scholar 

  3. Bardor, M. et al. Glycobiol. 13, 427–434 (2003).

    Article  CAS  Google Scholar 

  4. Landry, N. et al. PLoS One 5, e15559 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ward, B.J. et al. Vaccine 32, 6098–6106 (2014).

    Article  CAS  PubMed  Google Scholar 

  6. US Food and Drug Administration. Guidance for Industry, Safety Labeling Changes—Implementation of Section 505(o)(4) of the FD&C Act. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm250783.pdf (FDA, July 2013).

  7. Tekoah, Y. et al. Plant Biotechnol. J. 13, 1199–1208 (2015).

    Article  CAS  PubMed  Google Scholar 

  8. US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022458s003s006lbl.pdf (2014).

  9. Broomfield, A., Jones, S.A., Hughes, S.M. & Bigger, B. W. J. Inherit. Metab. Dis. doi:10.1007/s10545-016-9917-1 (2016).

  10. US Food and Drug Administration. Cerezyme (imiglucerase for injection): proposed text of the labeling of the drug. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf (FDA, March 2003).

  11. US Food and Drug Administration. Highlights of prescribing information for VPRIV. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022575s017lbl.pdf (FDA, April 2015).

  12. European Medicines Agency. European public assessment report (EPAR) summary for the public for Cerezyme. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000157/WC500024108.pdf

  13. Bosch, D., Castilho, A., Loos, A., Schots, A. & Steinkellner, H. Curr. Pharm. Des. 19, 5503–5512 (2013).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yoseph Shaaltiel & Yoram Tekoah are in the R&D Department, Protalix Ltd., Carmiel, Israel.,

    Yoseph Shaaltiel & Yoram Tekoah

Authors
  1. Yoseph Shaaltiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoram Tekoah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yoseph Shaaltiel or Yoram Tekoah.

Ethics declarations

Competing interests

The authors are employees of Protalix Ltd.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shaaltiel, Y., Tekoah, Y. Plant specific N-glycans do not have proven adverse effects in humans. Nat Biotechnol 34, 706–708 (2016). https://doi.org/10.1038/nbt.3556

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3556

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation